2024-09-15 - Analysis Report
##  Stock Analysis Report: ABT (Abbott Laboratories)

**Company Overview:** Abbott Laboratories is a global healthcare company that develops, manufactures, and markets a diverse range of medical devices, pharmaceuticals, and nutritional products.

**1. Performance Analysis:**

* **Relative Performance:**  ABT has underperformed the S&P 500 (VOO) over the period analyzed, with a cumulative return of 46.16% compared to the S&P 500's 87.74%. This results in a  -41.58% underperformance, placing ABT at the 21.52 percentile of its historical performance relative to the S&P 500. 

**2. Recent Price Movements:**

* **Closing Price:** $116.83
* **5-Day Moving Average:** $116.17
* **20-Day Moving Average:** $113.43
* **60-Day Moving Average:** $108.09

The recent price movements show a slight upward trend, with the closing price above all moving averages. This suggests potential short-term momentum.

**3. Technical Indicators:**

* **RSI:** 74.76  - The RSI is in the overbought territory, suggesting a potential for a short-term correction.
* **PPO:** 0.15 - The PPO is positive, indicating a bullish signal.
* **Relative Divergence:**  A 4.06% increase in the 20-day relative divergence indicates a potential for short-term upward price movement.
* **Expected Return:** 24.99% - This represents the estimated maximum 5-year return on investment based on current market conditions. 

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-07-31 | 0.74 | 10.38 B$ |
| 2024-05-02 | 0.7 | 9.96 B$ |
| 2023-11-01 | 0.82 | 10.14 B$ |
| 2023-08-03 | 0.79 | 9.98 B$ |
| 2024-07-31 | 0.79 | 9.98 B$ |

The most recent earnings report (2024-07-31) shows an EPS of 0.74, slightly above the estimated 0.72. The revenue of $10.38B slightly exceeded analyst expectations as well. This suggests continued strong financial performance for ABT. 

**5.  Summary Analysis:**

ABT has underperformed the S&P 500 over the analyzed period, but shows signs of recent momentum and potential for future growth.  While the stock is currently in overbought territory (high RSI), positive PPO, relative divergence, and strong recent earnings suggest a short-term upward trend could continue. However, the high valuation compared to the S&P 500,  indicates that ABT may be susceptible to volatility.  Investors should monitor the company's financial performance, market sentiment, and overall economic conditions for potential changes in the stock's direction. 
